Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($137.91K) by net assets ($230.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Drugs Made In America Acquisition Corp. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2024–2024)
This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Drugs Made In America Acquisition Corp. for a breakdown of total debt and financial obligations.
Drugs Made In America Acquisition Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition Corp. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Challenge Textile Co Ltd
SHE:002486
|
0.068x |
|
Cigniti Technologies Limited
NSE:CIGNITITEC
|
0.168x |
|
Kalekim Kimyevi Maddeler Sanayi & Ticaret AS
IS:KLKIM
|
0.033x |
|
Shandong Huapeng Glass Co Ltd
SHG:603021
|
0.035x |
|
Adlai Nortye Ltd. American Depositary Shares
NASDAQ:ANL
|
-1.791x |
|
Dynasty Ceramic Public Company Limited
BK:DCC
|
0.037x |
|
Egis Technology
TWO:6462
|
-0.020x |
|
Nu Skin Enterprises Inc
NYSE:NUS
|
0.034x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2024)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2024. For the full company profile with market capitalisation and key ratios, see Drugs Made In America Acquisition Corp. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-244.85 | $-172.26K | 703.553x | -- |
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.